Date: February 17, 2022

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:

Mycobacterium tuberculosis

  • Updated references and rationales.
  • Updated drug–drug interactions.
  • Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy.
  • Clarified that, for the treatment of drug-resistant tuberculosis, it is possible to use drug regimens with total duration as short as 6 to 12 months total when bedaquiline is part of the regimen instead of the 18 to 20 months total duration suggested by other sources.

For a list of recent updates, please see What's New in the Guidelines. To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infection Guidelines section of Clinical Info’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.

Clinical Info Welcomes Your Feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Please send your comments with the subject line “Adult and Adolescent Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by March 11, 2022.